Mipomersen, an antisense oligonucleotide against apolipoprotein B [68–71], had the potential benefit to reduce Lp(a) by 20%, but this drug is approved by the FDA only as an orphan drug for homozygous familial hypercholesterolemia [72]. The gene discussed is APOB; the disease is familial hypercholesterolemia.